chromium has been researched along with picibanil in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, SU; Akira, S; Furuichi, S; Moriya, Y; Nishioka, Y; Okamoto, M; Oshikawa, T; Ryoma, Y; Saito, M; Sato, M; Sone, S; Takeda, K; Tano, T | 1 |
1 other study(ies) available for chromium and picibanil
| Article | Year |
|---|---|
Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Topics: Adjuvants, Immunologic; Adult; Aged; Animals; Antigens, CD; Antigens, Surface; Antineoplastic Agents; Chemokines; Chromium; Combined Modality Therapy; Cytokines; Dendritic Cells; Female; Head and Neck Neoplasms; Humans; Immunotherapy; Interferon-gamma; Lymphocyte Antigen 96; Lymphocytes, Tumor-Infiltrating; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms, Experimental; Picibanil; Receptors, Cell Surface; RNA, Messenger; Streptococcus; T-Lymphocytes, Cytotoxic; Th1 Cells; Toll-Like Receptor 4; Toll-Like Receptors | 2004 |